Pirtobrutinib OK'd for chronic and small lymphocytic leukemia

FDA has expanded the indications for pirtobrutinib (Jaypirica), previously approved for mantle cell lymphoma, to include adults with CLL or SLL who've received ≥2 lines of therapy, including a BTK inhibitor and BCL-2 inhibitor. Approval was based on data from the phase 1/2 BRUIN trial (N=108), which showed a 72% overall response rate.